The lawsuit alleges that under an agreement signed with Watson Pharmaceuticals, Amphastar has given right to market, sell and distribute Enoxaparin Sodium Injection in the US, infringing Momenta’s US patent nos. 7,790,466 and 7,575,886
Enoxaparin Sodium Injection is the generic version of Lovenox of Sanofi-aventis and is indicated for the treatment of deep vein thrombosis and prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction.